Xilio Therapeutics Inc(XLO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.69 | Insider Own | 54.88% | Shs Outstand | 6.6M | Perf Week | -10.98% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 31.08% | Insider Trans | - | Shs Float | 3.0M | Perf Month | -10.18% |
| Enterprise Value | -0.08B | PEG | - | EPS next Q | -0.94 | Inst Own | 27.39% | Short Float | 13.81% | Perf Quarter | -7.17% |
| Income | -0.02B | P/S | 0.82 | EPS this Y | 31.26% | Inst Trans | 2.12% | Short Ratio | 30.31 | Perf Half Y | -5.19% |
| Sales | 0.06B | P/B | 0.73 | EPS next 5Y | 10.49% | ROA | -15.16% | Short Interest | 0.41M | Perf YTD | -10.41% |
| Book/sh | 10.98 | P/C | 0.39 | EPS past 3/5Y | 54.7% 31.67% | ROE | -55.03% | 52W High | -36.19% ($12.58) | Perf Year | -23.81% |
| Cash/sh | 20.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | -28.3% | 52W Low | 24.2% ($6.47) | Perf 3Y | -70.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.65% | Gross Margin | 97.91% | Volatility(W/M) | 6.6% 4.41% | Perf 5Y | -96.42% |
| Dividend TTM | - | EV/Sales | -1.2 | Sales Y/Y TTM | 327.25% | Oper. Margin | -48.94% | ATR (14) | 0.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.25 | EPS Q/Q | 85.72% | Profit Margin | -34.06% | RSI (14) | 29.67 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.25 | Sales Q/Q | 131.22% | SMA20 | -9.41% ($8.86) | Beta | -0.12 | Target Price | $18 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/12 | SMA50 | -10.62% ($8.98) | Rel Volume | 1.14 | Prev Close | $8.43 |
| Employees | 76 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | 44.07% 46.95% | SMA200 | -6.04% ($8.55) | Avg Volume(3M) | 0.01M | Price | $8.03 |
| IPO | 2021/10/22 | Option/Short | No/Yes | Trades | 128 | Volume | 15,380 | Change | -4.74% |
🧬 This is a clinical-stage biotech developing next-generation immuno-oncology drugs that are selectively activated only in the tumor microenvironment. Its lead candidate, vilastobart (XTX101), is a CTLA-4 antibody currently in Phase 2 clinical trials for solid tumors such as colorectal cancer, and the company is also continuing collaborative research with AbbVie. It is a pre-revenue company in the research and development stage.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded about as much as usual. That is 114% of its average volume.
XLO has a sound balance sheet but weak earning power
Of every $100 in sales, $48.94 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $82. Peers typically go for $1,138.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.4%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 27.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #412 of 594 in the industry
Based on market cap of $53M.
PLRX#410 Pliant Therapeutics Inc $54M PER - 
ELOX#411 Eloxx Pharmaceuticals Inc $53M PER - XLO#412 Xilio Therapeutics Inc $53M PER - 
ELTX#413 Elicio Therapeutics Inc $53M PER - 
RNTX#414 Rein Therapeutics Inc $52M PER - 
FAQ
What kind of company is XLO?
XLO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XLO?
The market cap of XLO is approximately $53M, ranking 4,826 within its sector.
What is the 52-week high and low for XLO?
XLO has recorded a 52-week high of $12.58 and a low of $6.47.
